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Figure 3.10 Agarose gel electrophoresis result of PCR screening of sucrose 
selected rtxC::aphA merodiploids for 996 bp WT rtxC and 2.0 
kb rtxC::aphA PCR amplicons using rtxC-F1 and rtxC-R1 
primers 
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Figure 3.11 Agarose gel electrophoresis result of PCR screening of sucrose 
selected rtxC-rtxC::aphA merodiploids for 1.4 kb SacB PCR 
amplicons using SacB-F2 and SacB-R primers 
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Figure 3.12 Construction of VCUSM10 (ΔrtxC/A) of ALA auxotrophic 
O139 V. cholerae mutant  
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Figure 3.13 Panel A, diagrammatic representation of pTZ57R-rtxC::aphA 
and restriction enzyme sites for PsyI. Panel B, agarose gel 
electrophoresis result of PsyI digested pTZ57R-rtxC::aphA 
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Figure 3.14 Panel A, diagrammatic representation of pTZ57R-∆rtxA/C. 
Panel B, agarose gel electrophoresis result of PCR screening of 
transformed colonies for 656 bp ∆rtxA/C PCR amplicons 
using rtxC-F1 and rtxC-R1 primers 
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Figure 3.15 Panel A diagrammatic representation of pTZ57R-∆rtxA/C. 
Panel B, agarose gel electrophoresis result of SacI and SalI 
digested pTZ57R-∆rtxA/C 
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Figure 3.16 Panel A, diagrammatic representation of pWM91-∆rtxA/C. 
Panel B, agarose gel electrophoresis result of PCR screening of 
transformed colonies for 656 bp of ∆rtxA/C PCR amplicons 
using rtxC-F1 and rtxC-R1 primers 
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Figure 3.17 Agarose gel electrophoresis result of PCR screening of 
rtxC::aphA-∆rtxA/C merodiploids for 2.0 kb rtxC::aphA and 
656 bp ∆rtxA/C PCR amplicons using rtxC-F1 and rtxC-R1 
primers 
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Figure 3.18 Agarose gel electrophoresis result of PCR screening of sucrose 
selected rtxC::aphA-∆rtxA/C merodiploids for 2.0 kb 
rtxC::aphA and 656 bp ∆rtxA/C PCR amplicons using rtxC-F1 
and rtxC-R1 primers 
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Figure 3.19 Agarose gel electrophoresis result of PCR screening of sucrose 
selected rtxC::aphA-∆rtxA/C merodiploids for 1.4 kb SacB 
PCR amplicons using SacB-F2 and SacB-R primers 
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Figure 3.20 Agarose gel electrophoresis result of PCR screening of sucrose 
selected ΔhemA-hemA/M merodiploids for 1.4 kb SacB PCR 
amplicons using SacB-F2 and SacB-R primers for VCUSM9 
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Figure 3.21 Agarose gel electrophoresis result of PCR screening of sucrose 
selected ΔhemA-hemA/M merodiploids for 1.4 kb SacB PCR 
amplicons using SacB-F2 and SacB-R primers for VCUSM10 
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Figure 3.22 Agarose gel electrophoresis result of PCR screening of sucrose 
selected ΔhemA-hemA/M merodiploids for 1.4 kb SacB PCR 
amplicons using SacB-F2 and SacB-R primers for VCUSM14 
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Figure 4.1 Phenotypic characterization of constructed V. cholerae mutant 
strains 
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Figure 4.2 Production of cholera toxin by VCUSM9P, VCUSM10P, 
VCUSM14P and WT O139 V. cholerae in LB broth at 30oC 
with shaking at 200 rpm for 12 hrs (n=4) 
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Figure 4.3 Biofilm formation by WT O139 V. cholerae, VCUSM9P, 
VCUSM10P and VCUSM14P in LB broth at 30oC after (A)12 
hrs, (B)24 hrs  and (C)48 hrs. Red circles indicate the 
formation of biofilm 
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Figure 4.4 Biofilm formation by WT O139 V. cholerae, VCUSM9P, 
VCUSM10P and VCUSM14P in LB broth at 37oC after (A)12 
hrs, (B)24 hrs  and (C)48 hrs. Red circles indicate the 
formation of biofilm 
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Figure 4.5 Haemolysis of chicken RBC by WT O139 V. cholerae, 
VCUSM9P, VCUSM10P and VCUSM14P at room 
temperature after 12 hrs of incubation with bacterial cell 
concentration of  A) 108 CFU/ml and B) 106 CFU/ml. O1 
Classical Inaba V. cholerae strain was used as negative control 
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Figure 4.6 Haemolysis of RBC in commercial horse blood agar by WT 
O139 V. cholerae, VCUSM9P, VCUSM10P and VCUSM14P 
at 37oC after 16 hrs of incubation. Halo regions indicate the 
lysis of horse RBC by the vibrios 
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Figure 4.7 Protease activity by WT O139 V. cholerae, VCUSM9P, 
VCUSM10P and VCUSM14P in modified LB agar with 5% 
skim milk at 37oC for 16 hrs. Halo areas surrounding the 
bacterial cells indicate utilization of casein in the agar medium 
as a result of protease activity 
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Figure 4.8 Swarming activity of WT O139 V. cholerae, VCUSM9P, 
VCUSM10P and VCUSM14P in motility agar plate incubated 
at room temperature for 24 hrs. The motility was measured by 
the size of the motility zone 
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Figure 4.9 The Cytotoxicity effect of V. cholerae strains on HEp-2 cells 
in culture. Subconfluent HEp-2 monolayer were exposed for 
1hr at m.o.i. of 100 with PBS as negative control (blank) 
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Figure 4.10 The action cross-linking activities of V. cholerae strains on 
HEp-2 cells in culture. At 1 hr after infection, cells were 
resuspended in sample buffer, boiled and subjected to SDS–
PAGE and Western blotting with an anti-actin antibody 
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Figure 4.11 In vitro colonization of WT O139 V. cholerae, VCUSM9P, 
VCUSM10P and VCUSM14P in differentiated HT-29 cell 
lines (n=4) 
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Figure 4.12 IL-6 secretion by HT-29 infected with WT O139 V. cholerae, 
VCUSM9P, VCUSM10P and VCUSM14P at 2 hrs, 4 hrs and 
8 hrs intervals, (n=2) 
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Figure 4.13 IL-8 secretion by HT-29 cells infected with WT O139 V. 
cholerae, VCUSM9P, VCUSM10P and VCUSM14P at 2 hrs, 
4 hrs and 8 hrs intervals, (n=2) 
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Figure 4.14 TNF-α secretion by HT-29 cells infecteds with WT O139 V. 
cholerae, VCUSM9P, VCUSM10P and VCUSM14P at 2 hrs, 
4 hrs and 8 hrs intervals, (n=2) 
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Figure 4.15 Intestinal colonization 
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Figure 4.16 Immunohistochemical detection of WT O139 V. cholerae, 
VCUSM9P, VCUSM10P and VCUSM14P intestinal 
colonization in 3-5 days old suckling mice. The vibrios were 
identified as brown staining (red arrows). Original 
magnification X200 
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Figure 4.17 Ileal loop assay of WT O139 V.cholerae, WT O1 V. cholerae, 
VCUSM9P, VCUSM10P and VCUSM14P in rabbit small 
intestine 
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Figure 4.18 Histopathological features of rabbit ileum section infected with 
WT O139 V. cholerae. The muscular layer (thick arrow) and 
villi of the mucosal layer (thin arrows) were severely damaged. 
Original magnification X200 
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Figure 4.19 Histopathological features of rabbit ileum section infected with 
VCUSM9P. The villi (thin arrow) of the mucosal layer were 
severely blunted and RBCs (thick arrow) were detected in 
between muscle fibers. Original magnification X200 
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Figure 4.20 Histopathological features of rabbit ileum section infected with 
VCUSM10P . The villi (thin arrow) of the mucosal layer suffer 
from mild blunting, haemorrhage (thick arrow) and congested 
blood vessels (arrow head) were also observed within the 
tissue. Original magnification X200  
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Figure 4.21 Histopathological features of rabbit ileum section infected with 
VCUSM14P.  The mucosal and muscular layer were intact in 
the tissue. Original magnification X100 
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Figure 4.22 Immuno histochemical staining of rabbit ileum sections 
infected with (A) WT O139 V. cholerae, (B) VCUSM9P, (C) 
VCUSM10P and (D) VCUSM14P*. The vibrios were 
identified as brown staining (red arrows). Original 
magnification X20 *Original magnification is X400 
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Figure 4.23 Scanning electron microscopy of rabbit ileum infected with 
(A) WT O139 V. cholerae, (B) VCUSM9P, (C) VCUSM10P 
and (D) VCUSM14P. The vibrios were observed colonizing 
the mucosal surface of the intestine. Original magnification 
X5000 
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Figure 4.24 Transmission electron microscopy of rabbit ileum section 
infected with WT O139 V. cholerae. The vibrios (thick 
arrows) appear to be endocytosed by APC (arrow heads) in 
between muscle fiber (thin arrow). N represents nucleus of the 
APC. Original magnification X4500 
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Figure 4.25 Transmission electron microscopy of rabbit ileum section 
infected with VCUSM9P. The vibrios (thick arrows) appear to 
be endocytosed by APC (arrow heads) in between muscle fiber 
(thin arrow).N represents nucleus of the APC. Original 
magnification X4500 
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Figure 4.26 Transmission electron microscopy of rabbit ileum section 
infected with VCUSM10P. The vibrios (thick arrows) appear 
to be endocytosed by APC (arrow heads) in between muscle 
fiber (thin arrow).N represents the nucleus of APC. Original 
magnification X4500 
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Figure 5.1 Scanning electron microscopy of VCUSM14P immunized 
rabbit’s small intestine after RITARD challenge with wild type 
O139 V. cholerae.  Original magnification X250 and X9210 
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Figure 5.2 Geometric mean titer (GMT) of anti-cholera toxin IgA and 
IgG antibodies in VCUSM14P vaccinated rabbits (n=3) 
 
 167 
Figure 5.3 Geometric mean titer (GMT) of anti-lipopolysaccharide IgA 
and IgG antibodies in VCUSM14P vaccinated rabbits (n=3) 
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Figure 5.4 Geometric mean titer of vibriocidal antibodies in VCUSM14P 
vaccinated rabbits (n=3) 
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PEMBANGUNAN VAKSIN KOLERA MELALUI PEMAHAMAN MEKANISMA 
MOLEKUL ENTEROPATOGENESIS BAGI MUTASI GEN-GEN TOKSIN MARTX 
DAN GEN TOKSIN KOLERA VIBRIO CHOLERAE KUMPULAN SERO O139 
 
ABSTRAK 
 
Kolera merupakan penyakit cirit-birit yang boleh membawa maut. Ia disebabkan oleh 
mikroorganisma V. cholerae kumpulan sero O1 dan O139 yang bertoksik. Pengesanan awal 
kolera dan rawatan segera ke atas pesakit adalah amat diperlukan bagi mencegah berlakunya 
kematian. Walaupun penyebaran penyakit ini dapat dikawal dengan penyediaan sistem 
kumbahan yang teratur, namun cara terbaik untuk mengatasinya adalah melalui program 
vaksinasi. Terdapat beberapa vaksin kolera bagi V. cholerae kumpulan sero O1 namun, 
vaksin-vaksin ini tidak dapat mencegah jangkitan daripada V. cholerae kumpulan sero O139. 
Walaupun terdapat vaksin kolera bivalen O1/O139, ujian klinikal menunjukkan gerakbalas 
imun pelindungan terhadap kumpulan sero O139 adalah kurang memuaskan. Maka, objektif 
dalam kajian ini adalah untuk menghasilkan vaksin hidup teratenuat kolera terhadap V. 
cholerae kumpulan sero O139. Kajian ini berfokus kepada analisis terhadap kesan mutasi 
bagi toksin MARTX dan toksin kolera dalam V. cholerae kumpulan sero O139. Ciri-ciri 
sitotoksik mutan rtxC (VCUSM9P) dan mutan rtxA/C (VCUSM10P) V. cholerae kumpulan 
sero O139 didapati hilang. Analisis “Western blot” menunjukan mutasi gen rtxC sahaja 
adalah tidak memadai untuk menghapuskan kesan toksik toksin MARTX. Kesan reaktogenik 
pada model gelung ileum arnab bertambah walaupun aktiviti toksin MARTX mutan rtxC dan 
rtxA/C berkurang. Walaubagaimanapun, mutan ctxA (VCUSM14P) dengan CT-A yang telah 
dinyahaktif tidak menunjukkan sebarang kesan reaktogenik pada model gelung ileum arnab 
dan masih mengekalkan aktiviti sitotoksik yang sama sepertimana yang ditunjukkan genotip 
liar O139 V. cholerae pada sel-sel HEp-2. Selain daripada itu, mutan-mutan MARTX dan 
CT juga berupaya untuk mencetuskan rembesan sitokin-sitokin proinflamasi dalam sel-sel 
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HT-29 yang telah dijangkiti. Maka, strain mutan yang tidak reaktogenik VCUSM14P telah 
dipilih untuk kajian pemvaksinan seterusnya. Setelah pemvaksinan dua dos VCUSM14P 
melalui laluan oral, didapati antibodi-antibodi anti-CT, anti-LPS dan “vibriocidal” dihasilkan 
pada titer yang tinggi. Kajian cabaran juga menunjukkan perlindungan terhadap jangkitan V. 
cholerae kumpulan sero O139. Kesimpulannya, dengan kajian eksperimen kami telah 
membuktikan mutasi pada toksin MARTX tidak mengurangkan kesan reaktogenik dalam V. 
cholerae O139 kumpulan sero O139 dan juga kesan mutasi tunggal terhadap gen rtxC adalah 
tidak memadai untuk merencatkan funsi paut silang aktin toksin MARTX. Selain itu, 
penilaian ke atas VCUSM14P menunjukkan potensi mutan ctxA sebagai calon vaksin kolera 
yang tidak reaktogenik dan selamat terhadap V. cholerae kumpulan sero O139.   
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UNDERSTANDING THE MOLECULAR ENTEROPATHOGENESIS OF MARTX 
TOXIN GENES AND CHOLERA TOXIN GENE MUTATION OF VIBRIO 
CHOLERAE  O139 SEROGROUP TOWARDS CHOLERA VACCINE 
DEVELOPMENT 
 
ABSTRACT 
 
Cholera is a lethal diarrheal disease caused by toxigenic V. cholerae of O1 and O139 
serogroups. Early diagnosis and prompt treatments of the disease are needed to prevent death 
in these patients. Even though the spreading of the disease could be controlled with proper 
sanitation, the best way to prevent cholera is through vaccination. There are several cholera 
vaccines available for O1 serogroup V. cholerae but they do not cross-protect against O139 
serogroup. The bivalent O1/O139 cholera vaccine also did not show satisfactory protective 
immune response against O139 serogroup in clinical trials. Hence, the objective of this study 
is to construct an attenuated live cholera vaccine against V. cholerae O139 serogroup. In the 
present study, we focused on mutational analysis of MARTX toxin and cholera toxin of V. 
cholerae O139 serogroup. Constructed rtxC (VCUSM9P) and rtxA/C (VCUSM10P) mutants 
of V. cholerae O139 serogroup showed depleted in cytotoxic properties. Western blot 
analysis indicated mutation of rtxC gene alone is not sufficient to abolish MARTX toxin 
toxicity. Despite disrupted MARTX toxin activity in rtxC and rtxA/C mutants, increase 
reactogenicity were observed in ileal loop model. However, ctxA mutant (VCUSM14P) with 
mutated CT-A did not show any reactogenicity in ileal loop model, but retain MARTX 
cytotoxicity activity similar to WT O139 strain in HEp-2 cells. These MARTX and CT 
mutants were also found to induce proinflammatory cytokines in infected HT-29. Non-
reactogenic mutant strain, VCUSM14P, was selected for vaccination study. High titers of 
anti-CT, anti-LPS and vibriocidal antibodies were induced after two regimens vaccination 
through oral route of VCUSM14P. Challenge study with VCUSM14P also showed 
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protection against WT O139 V. cholerae. In conclusion, we have experimentally proven that 
the MARTX toxin mutation does not reduce reactogenicity in V. cholerae O139 serogroup 
and mutation in rtxC alone do not completely remove the actin crosslinking property of 
MARTX toxin. The evaluation on VCUSM14P vaccine indicated that it is a non-reactogenic 
and protective vaccine candidate against V. cholerae O139 serogroup. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Cholera 
Cholera is a diarrheal disease caused by certain types of Vibrio cholerae. It begins with 
sudden onset of massive diarrhea, with the loss of enormous amount of protein-free fluid. 
The loss of electrolytes, bicarbonates and ions within short period of time will results in 
hypovolemic shock and acidosis in the patients (Chaudhuri and Chatterjee, 2009a, Tauxe, 
1998). If left untreated without prompt attention, the resulting dehydration will lead to 
tachycardia, hypotension, and also vascular collapse that will lead to deaths (Chaudhuri and 
Chatterjee, 2009a, Ryan, 2004). 
 
1.2 Vibrio cholerae  
V. cholerae, a member of the family Vibrionaceae, is a facultative anaerobic, Gram-negative, 
non-spore-forming and highly motile organism with the length of 1.4-2.6 μm (Kay et al., 
1994). The genus Vibrio also includes many different species, of which V. parahaemolyticus, 
V. alginolyticus, V. mimicus, and V. vulnificus are associated with human diseases (Sakazaki, 
1992). Among the vibrio species, V. cholerae is a well-defined species based on biochemical 
tests. The Vibrio species can be differentiated by a variety of tests as shown in Table 1.1. 
Most of the environmental V. cholerae are non-pathogenic and the organism became 
pathogenic mainly through acquiring virulence genes by lateral gene transfer from other 
species (Gonzalez-Fraga et al., 2008).  
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Table 1.1 Biochemical tests for differentiation of V. cholerae from related species (Adapted 
from table 2, Kaper et al., 1995). 
Test  V. cholerae Other Vibrio species 
Oxidase + +a 
String test + +/– 
Acid from mannitol + +/– 
Acid from sucrose + +/– 
Lysine decarboxylase + +/– 
Arginine dihydrolase – +/– 
Ornithine decarboxylase + +/– 
Growth in 0% NaCl + –b 
 
aExcept for V. metchnikovii 
bExcept for V. mimicus 
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1.2.1 Taxanomy of V. cholerae  
The taxanomy of V. cholerae is given below: 
Kingdom  : Bacteria 
Phylum  : Proteobacteria 
Class  : Gamma Proteobacteria 
Order  : Vibrionales 
Family  : Vibrionaceae 
Genus  : Vibrio 
Species  : Vibrio cholerae 
  
1.2.2  Subtyping 
V. cholerae is not homogeneous in many aspects and subtyping of the species are based on 
important distinctions within the species such as serogroup, cholera enterotoxin production 
and potential for epidemic spread.  
 
1.2.2.1 Serogroup 
Serogrouping are based on highly diverse heat-stable lipopolysaccharide O-antigen produced 
by V. cholerae. The heat-stable lipopolysaccharide O-antigen can be differentiated by its 
differences in the sugar composition of the terminal sugar group (Shimada et al., 1994, 
Tauxe, 1998). Currently, there are around 200 serogroups (O1 to O200) of V. cholerae had 
been identified, and more may surface in the future (Shimada et al., 1994).  Before 1992, all 
major epidemics of cholera were exclusively caused by the O1 serogroup of V. cholerae 
strains and the simple distinction of V. cholerae O1 and V. cholerae non-O1 was used for 
classification. But in 1993, the emergence V. cholerae O139 as new serogroup associate with 
cholera (Faruque et al., 2003, Morris, 1994), the designation of V. cholerae non-O1 non-
O139 has been used to categorize the epidemic causing serogroups of V. cholerae O1 and 
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O139 (Kaper et al., 1995). To date, only strains from V. cholerae O1 and O139 serogroups, 
which produce cholera toxin (Angelichio et al., 1999) are associated with epidemic cholera 
(Trucksis et al., 1993). Strains of these serogroups which do not produce CT are unable to 
cause cholera and are not involved in epidemics. V. cholerae of serogroups other than O1 
and O139 do occasionally produce cholera outbreaks, but yet to cause large epidemic or 
worldwide pandemic (Kaper et al., 1995). The emergence of V. cholerae O139 as new 
serogroup associated with cholera, and its possible evolution from horizontal gene transfer 
between O1 and non-O1 strains (Bik et al., 1995), has led to heightened interest in the study 
of V. cholerae non-O1 non-O139 serogroups. 
  
1.2.2.2 Biotypes 
V. cholerae O1 serogroup consists of two different biotypes, classical and El Tor (Kaper et 
al., 1995). These subdivisions are based on several characteristics and are as described in 
Table 1.2. It is believed that V. cholerae O1 serogroup classical biotype was the causative 
agent for the first six cholera pandemic and the El Tor biotype caused the seventh cholera 
pandemic (Blake, 1994).  
 
1.2.2.3 Serotypes 
Classical and El Tor biotypes are subdivided into two major serotypes, Ogawa and Inaba, 
through their antigenic factors. Ogawa serotype is said to express A and B antigens and 
small amount of C antigen, whereas Inaba serotype express only the A and C antigens. A 
third serotype, Hikojima, which is rare and unstable is said to express all three antigens - A, 
B and C (Kaper et al., 1995, Stroeher et al., 1992).  
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 Table 1.2 Differentiation of classical and El Tor biotypes of V. cholerae O1 (Adapted from 
table 4, Kaper et al., 1995). 
Test Used 
Result 
Classical El Tor 
Haemolysis – +/– 
Agglutination of chicken erythrocytes – + 
Voges-Proskauer reaction – + 
Inhibition by polymyxin B (50-U disc) + – 
Lysis by Group IV cholera phage + – 
Lysis by FK cholera phage + – 
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1.2.3 CTX phage 
Cholera toxin is encoded by ctxAB genes which are part of a gene cluster normally referred 
to as CTX genetic element (Davis and Waldor, 2003, Pearson et al., 1993). Initial studies 
had revealed that ctxAB genes were only present in toxigenic V. cholerae (Trucksis et al., 
1993). It was also discovered that the ctxAB genes were not integral components of the V. 
cholerae genome, but instead correspond to the genome of an integrated filamentous 
bacteriophage designated CTXφ (Waldor and Mekalanos, 1996). The CTXφ genome has two 
regions, the “core” and RS2. The core region contains the genes encoding CT (ctxA/B), 
zonula occludens toxin (zot), accessory toxin (ace), core-encoded pilin (cep) and functions 
related to phage morphogenesis (Waldor and Mekalanos, 1996). The RS2 region contains 
three open reading frame (ORF), designated rstR, rstA, and rstB, and two apparently 
untranslated regions called intergenic regions Ig-1 and Ig-2 (Boyd et al., 2000). These genes 
code for products that control phage replication and site-specific integration. The CTXφ 
prophage is often flanked by a related genetic element known as the RS1. The RS1 element 
is very similar to the RS2 region of CTXφ in genetic and functional aspects (Waldor et al., 
1997). Different from RS2, RS1 carries an additional ORF termed rstC, which serve as 
antirepressor that controls CTXφ lysogeny, production of CTXφ particles, and expression of 
cholera toxin (Davis et al., 2002). The CTX genetic elements are as shown in Figure 1.1. The 
CTXφ utilizes the toxin-coregulated pili (TCP) as its functional receptor for infection of V. 
cholerae cells (Heilpern and Waldor, 2000, Levin and Tauxe, 1996). Understanding the 
mode of integration of phage DNA into the host chromosome has been a problem and two 
different views have been separately proposed by McLeod and Waldor (2004) and Val et al. 
(2005). Two chromosome-encoded tyrosine recombinases, XerC and XerD, were found to 
assist in the recombination process that leads to integration of phage DNA into host 
chromosome of V. cholerae (Huber and Waldor, 2002, McLeod and Waldor, 2004, Val et 
al., 2005). The CTXφ phage enters into a lysogenic state following its integration into the  
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Figure 1.1 Panel A, schematic representation of the genetic organization of CTXφ 
comprising an RS2 region and a core region. Panel B, schematic representation of the 
genetic organization of RS1 element. Solid arrows represent ORFs, whereas bend arrows 
indicate the promoters for rstR, rstA and ctxAB. (Adapted from figure 1, Faruque et al., 
2002) 
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host chromosome. Like other filamentous phages, CTXφ is secreted from V. cholerae 
without cell lysis. 
 
1.3 Epidemiology 
There were 190,130 cholera cases reported from 53 countries worldwide to WHO in 2008, 
which involved 5,143 cases of death cause by cholera (WHO, 2009a). The figures represent 
7.6% increase in the number of cases and 27% increase in the number of deaths reported as 
compared with 2007. Prabably, the true number of cholera cases and deaths were far more 
than those reported. Due to the limitation in facilities and surveillance system in developing 
and under-develop countries, the under-reported cases were expected to be high. Besides, 
cases of reported cholera to WHO also excluded numerous cholera cases which were labeled 
as acute watery diarrhea (AWD) with estimated 500,000-700,000 cases. Figure 1.2 shows 
cholera cases reported by countries in year 2006-2008. 
 
1.3.1  Early pandemics 
There were six cholera pandemics recorded in the period of 1817-1923, and was described as 
early history of cholera (Kaper et al., 1995). Though, the dates of these pandemics differ 
among different writers as shown in Table 1.3. But, the most commonly used dates of the 
first six pandemics are of those proposed by Politzer (1959), the fifth and sixth pandemics 
were caused by V. cholerae of classical biotype, and it is believed that the earlier pandemics 
were also caused by classical biotype (Blake, 1994, Tauxe, 1998). 
 
1.3.2 Seventh pandemic, 1961-present 
The seventh cholera pandemic began in 1961, distinct from previous six pandemics; the 
causative agent was V. cholerae O1 El Tor biotype. The pandemic was originated from th
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Figure 1.2  Cholera, countries reporting outbreaks and imported cases, 2006-2008 (WHO, 2009b) 
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Table 1.3 Cholera pandemics 1817-1923/5 (Adapted from table 1: Chapter 1, Barua, 1992) 
Pandemic 
According to 
Haesser 
(1882) 
Hirsch 
(1883) 
Sticker 
(1912) 
Kolle and Priggs 
(1928) 
Pollitzer 
(1959) 
Wilson and Miles 
(1975) 
1 (a)1816-1823 
(b)1826-1837 
1817-1823 1817-1838 – 1817-1823 1817-1823 
2 1840-1850 1826-1837 1840-1864 – 1829-1851 1826-1837 
3 1852-1860 – 1863-1975 – 1852-1859 1846-1862 
4 1863-1873  1881-1896 – 1863-1879 1864-1875 
5 – – 1899 1883-1896 1881-1896 1883-1896 
6 – – – 1902-1923 1899-1923/5 1899-1923 
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island of Sulawesi in Indonesia and spread to the surrounding islands (Faruque et al., 1998). 
The entire Southeast Asia and Asian mainland were invaded with V. cholerae O1 El Tor 
biotype in between 1962-1969. By 1970s, the pandemic spread to the African continent and 
reached South America in 1990s with an explosive epidemic in Peru. The pandemic spread 
to surrounding countries in South America and further north to Central America (PAHO, 
1991). The pandemic is still ongoing, and it continues to cause seasonal outbreaks in many 
developing countries (Faruque et al., 1998). The emergence of V. cholerae O1 El Tor 
biotype has completely displaced classical biotype worldwide, except in Bangladesh where 
reappearance of the classical biotype at epidemic proportions in 1982 and persist for several 
years. But, the classical biotype seems to have become extinct again (Shimada et al., 1994, 
Siddique et al., 1991). 
 
1.3.3 Possibility of eighth pandemic 
In late 1992, a new cholera epidemic erupted in Madras, India and in Southern Bangladesh 
(Faruque et al., 1998). The causative organism isolated from this outbreak was V. cholerae 
of non-O1, which produced cholera toxin and is now known as V. cholerae O139 serogroup 
(Shimada et al., 1994). Rapid spreading of V. cholerae O139 serogroup to surrounding 
countries and Southeast Asia raise concern of the possibility of the eighth pandemic. 
Outbreaks or cases due to V. cholerae O139 have since been reported in countries such as 
Pakistan, Nepal, China, Thailand, Kazakhastan, Afganistan and Malaysia (Kaper et al., 
1995). Imported cases were also reported in the United Kingdom and United States of 
America. Surveillance during 1996 and 1997 has shown that V. cholerae O139 serogroup 
continues to cause cholera outbreaks in India and Bangladesh and coexists with the El Tor 
vibrios (Faruque et al., 1997).  
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1.4 Ecology of V. cholerae  
1.4.1  Environment  
V. cholerae is part of the normal, free-living bacterial flora in riverine and estuarine areas. It 
has been regarded as a member of organisms whose major habitats are aquatic ecosystems. 
But, toxigenic strains of V. cholerae O1 and O139 serogroups are rarely isolated from the 
environment, even in epidemic settings which fecal contamination of the environment might 
be expected (Faruque et al., 1998). However, CT-producing V. cholerae O1 and O139 can 
persist in environment with the absence of known human disease. The persistence of V. 
cholerae within the environment may be facilitated by its ability to assume survival forms, 
including viable but nonculturable state (VBNC) and the “rugose” survival form (Baker et 
al., 1983, Colwell and Huq, 2001). Microbiology studies also shown that zooplankton and 
phytoplankton plays a significant role as a reservoir for V. cholerae in the environment 
(Colwell and Huq, 2001, Tamplin et al., 1990), hence planktonic blooms had been related to 
seasonal outbreak of cholera (Alam et al., 2006). The V. cholerae was also found to be able 
to survive through attaching to the crustacean and algae from the aquatic environments 
(Castro-Rosas and Escartin, 2005, Colwell et al., 1992, Estrada-Garcia and Mintz, 1996). 
 
1.4.2  Human 
Human can serve as reservoir and source of toxigenic V. cholerae. Person with acute cholera 
can excrete 107-108 CFU of V. cholerae organisms per gram of stool and with the output of 
V. cholerae ranging from 1011-1013 CFU (Kaper et al., 1995). Even after cessation of 
symptoms, patients whom did not receive antibiotics treatment may continue to excrete 
vibrios for weeks (Dizon et al., 1967). In some cases, a very small minority of patients may 
continue to excrete the organism for even longer periods of time, for up to 10 years (Kaper et 
al., 1995). So it is suggested that the asymptomatic human carrier of the toxigenic V. 
cholerae is the primary reservoir for cholera. Yet, opposing views claim that humans do not 
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constitute a true reservoir for disease causing strains, but there is clearly a dynamic 
relationship between human and environmental sources of the organism.  
 
1.5 Pathogenesis 
1.5.1  V. cholerae infection 
Infection due to V. cholerae begins with the ingestion of food or water contaminated with the 
organism. Most of the vibrios will be killed by the low pH stomach condition. After 
surviving passage through the gastric acid barrier in the stomach, the vibrios will penetrate 
the mucous coat of the intestinal epithelium with the help of its motility properties and 
enzymes secretion (Faruque et al., 1998, Kaper et al., 1995). Upon reaching the endothelial 
surface, colonization of the organisms onto microvilli will be achieved with the help of 
toxin-coregulated pili (TCP) (Kaper et al., 1995, Tacket et al., 1998, Voss et al., 1996). The 
adhering vibrios through TCP activate expression and secretion of CT by V. cholerae that 
will disrupt ion transport in the intestinal epithelial cells and lead to subsequent loss of water 
and electrolytes (Field et al., 1972). The severity of symptoms varies with the V. cholerae 
strain ingested, the infection dose, the effect of gastric acid and also patient’s blood type 
(Tauxe, 1998).  
 
1.5.2 Cholera toxin 
Cholera toxin is the most significant pathogenic factor secreted by V. cholerae subsequent to 
colonization at the small bowel. The holotoxin CT (comprising the subunits A and B) are 
encoded by ctxAB genes which are part of a cluster of genes normally referred to as the CTX 
genetic element (Faruque et al., 1998). The CTX genetic element also carries the zot gene 
coding for zonula occludens toxin (Zot), the ace gene encoding accessory cholera toxin 
(Ace), a core-encoded pilin (cep) responsible for enhancing colonization and an open reading 
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frame (ORF) of unknown function (orfU) (Waldor and Mekalanos, 1996) as shown in Figure 
1.1. 
The enterotoxin is an oligomeric complex made up of six protein subunits: one A 
subunit (CT-A) and five B subunits (CT-B). The CT-B forms a symmetrical pentamer from 
five identical CT-B subunits with a cylindrical central pore (Chaudhuri and Chatterjee, 
2009b). While the A1 fragment of the CT-A subunit rest on the B pentamer, with the 
elongated A2 fragment alpha helix tail that extends through the pore of CT-B holotoxin. The 
A2 fragment alpha helix tail is mainly responsible for the interaction between the CT-A and 
CT-B subunits. In nature, the CT binds to ganglioside GM1 receptor in the intestinal 
epithelial cell by its CT-B subunits (Holmgren et al., 1975, Kaper et al., 1995).  Figure 1.3 
shows binding of CT to GM1 on the surface of epithelial cell membrane. Upon successful 
binding of pentameric CT-B to GM1, the entire CT were which are linked by an exposed 
loop containing a site for proteolytic cleavage (after arginine 192) and a disulfide bond that 
bridges the cleavage site are then proteolytically cleaved and reduced. This will generate 
enzymatically active A1 peptide, ADP-ribosyl transferase (22 kDa) and A2 peptide (5 kDa) 
(Chaudhuri and Chatterjee, 2009b). The A1 peptide migrates into the cytosol of the cell and 
activates adenylate cyclase by catalyzing the ADP-ribosylation of the subunit of the 
heterotrimeric GTPase (Lencer et al., 1993). This will cause a sustained increase of intestinal 
cAMP levels (Bennett et al., 1975), which results in excess secretion of isotonic fluid into 
the intestinal lumen. The A2 peptide forms the scaffolding that tethers the A and B subunits 
together (Chaudhuri and Chatterjee, 2009b).  
 
1.5.3  MARTX toxin 
Multifunctional autoprocessing repeat-in-toxin (MARTX) was discovered by Lin et al., 1999 
in a search for undiscovered potential virulence determinants in V. cholerae based on 
similarities to virulence genes of other pathogenic microorganisms (Lin et al., 1999). The 
MARTX gene cluster was uncovered during analysis for contigs located in the vicinity of the   
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Figure 1.3 Schematic diagram showing the binding of cholera toxin molecule through its 
pentameric CT-B to the GM1 pentasaccharides of the epithelial cell membrane. (Adapted 
from figure 7.7 Cholera Toxins, Chaudhuri and Chatterjee 2009c) 
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CTX genetic element. Four genes were found to display high degrees of similarity to the 
biogenesis of RTX toxins in several Gram-negative organisms. Hence, it is categorized in 
RTX toxin family of secreted bacterial cytotoxins. The RTX toxin nomenclature is derived 
from the presence of a C-terminal calcium-binding domain of acidic glycine-rich 
nonapeptide repeats in the members of the RTX toxin family. Most of V. cholerae isolates 
belonging to O1 El Tor, O139, and non-O1 non-O139 serogroups, exhibited intact MARTX 
gene clusters (Chow et al., 2001, Cordero et al., 2007). However, MARTX gene clusters in 
classical V. cholerae strains was found to have deletion that removes 5’ end of rtxA, whole 
rtxC and 5’ end rtxB (Lin et al., 1999). Hence, the classical V. cholerae strains do not cause 
cell rounding in eukaryotic cell lines.  
MARTX toxin of V. cholerae is encoded by rtxA gene which resides within the 
MARTX gene cluster together with rtxB, rtxC, rtxD, rtxE and VC1449 (Boardman and 
Satchell, 2004, Sheahan et al., 2004) as shown in Figure 1.4. These rtxB, rtxC, rtxD and rtxE 
genes play an important role in production and transportation of the MARTX toxin. The rtxC 
encodes an acyltransferase, which acts as an activator of MARTX toxin (Cheong et al., 
2010), whereas rtxB, rtxD and rtxE encode transportation proteins that are involved in the 
transport of the toxin into the environment. The VC1449 codes for a conserved hypothetical 
protein (Boardman and Satchell, 2004, Sheahan et al., 2004).  
Unlike members of RTX family of toxins, V. cholerae MARTX toxin does not 
disrupt membrane integrity and do not cause necrosis or leakage of cytoplasmic products 
(Lin et al., 1999, Saha et al., 1996). Functional analysis revealed that the toxin is responsible 
for the rounding and detachment of HEp-2 cells in vitro and mediate actin 
crosslinking(Cordero et al., 2007, Fullner and Mekalanos, 2000) or inactivation of Rho 
GTPases (Sheahan et al., 2007). Since then, the toxin was renamed as multifunctional 
autoprocessing repeat-in-toxin (MARTX). 
Despite the difference between MARTX of V. cholerae and other RTX toxins of 
Gram negative organisms, the MARTX of V. cholerae is also secreted by type 1 secreting 
system (T1SS) (Boardman and Satchell, 2004). Study by Boardman and Satchell (2004)  
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Figure 1.4 Schematic representation of the genetic organization of V. cholerae MARTX 
gene clusters. (Adapted from figure 1a, Boardman et al., 2004) 
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shows that V. cholerae MARTX toxin is secreted by a four component T1SS encoded by 
rtxB, rtxD rtxE and tolC. Comparatively, the rtxB operon is a putative ATPase gene and 
rtxD operon is a putative periplasmic linker protein gene. Both genes were overlapped by 46 
nucleotides and encodes proteins that are 63% and 50% similar to hlyB and hlyD genes 
exemplified by E. coli haemolysin T1SS (Lin et al., 1999). The rtxE operon which located 
downstream to rtxD, encodes a transport ATPase that is 63% similar to hlyB and 60% 
similar to rtxB of V. cholerae (Boardman and Satchell, 2004). The involvement of tolC 
which is unlinked to MARTX gene cluster in toxin secretion was proposed from evidence 
that the absence of cell rounding by V. cholerae in tolC mutant (Bina and Mekalanos, 2001).  
V. cholerae MARTX did not disrupt membrane integrity and did not cause leakage 
of cytoplasmic components in eukaryotic cells, which distinct it from pore forming RTX 
family of toxins. The toxin causes cell rounding of eukaryotic cell types such as Hep-2 and 
T84 cell lines without direct effect on cell viability by means of cytoskeleton alteration 
(Steele-Mortimer et al., 2000). It was proposed that cytoskeleton alteration by V. cholerae 
MARTX toxin occurs through two different pathways: either by actin crosslinking (Fullner 
and Mekalanos, 2000, Lin et al., 2000) or by Rho GTPases inactivation (Sheahan et al., 
2007), as illustrated in Figure 1.5. MARTX toxin targets globular monomer (G-actin), 
resulting in the crosslinking of actin into dimers, trimers, and higher-order crosslinked 
products, disrupting the equilibrium between filametous polymer (F-actin) and G-actin, 
ultimately resulting in F-actin disassembly and an increase in paracellular permeability 
(Fullner and Mekalanos, 2000). Cell rounding and actin depolymerization associated with 
MARTX was also prevented in Rho GTPases activation, suggesting involvement of Rho 
GTPase signaling pathways in MARTX activity. However, the extent to which these 
activities of RTX influence pathogenesis in vivo is largely unknown.  
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Figure 1.5 Mechanism of disruption of actin cytoskeleton by MARTX toxin by two different 
pathways: action crosslinking and Rho GTPase inactivation. (Adapted from figure 13.8, 
Cholera Toxins, Chaudhuri and Chatterjee, 2009a) 
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1.5.4 Other Toxins  
1.5.4.1  Haemolysin (Hly) 
Haemolysin of V. cholerae, often called V. cholerae cytolysin (VCC), is a 65 kDa exotoxin 
encoded by hlyA gene. It is produced by most V. cholerae, including many non-CT 
producing strains (Goldberg and Murphy, 1984, Honda and Finkelstein, 1979, Yamamoto et 
al., 1984). Mature VCC forms heptameric oligomers, insert into lipid bilayers to generate 
noncylindrical anionselective membrane pores about 1–2 nm in internal diameter (Galdiero 
and Gouaux, 2004). The VCC attacks red blood cell membranes and causes cell rupture with 
the liberation of haemoglobin (Honda and Finkelstein, 1979). It has been proposed that VCC 
contributes to the pathogenesis of gastroenteritis caused by V. cholerae, especially with non-
CT producing strains (Pichel et al., 2003), although the significance of VCC in the disease in 
humans has been questioned. 
 
1.5.4.2   Zonula occludens toxin (Zot) 
Zot is a single polypeptide chain of 44.8 kDa in size and 399 amino acids in length. It has a 
bacteriophagal origin, and is present in toxigenic strains of V. cholerae (Baudry et al., 1992, 
Fasano et al., 1991). Studies also showed that the activity of Zot is reversible, heat-labile and 
sensitive to protease digestion. The toxin reversibly alters the permeability of intestinal 
epithelial tight junctions, allowing the passage of macromolecules through mucosal barriers 
(Salama et al., 2006). This alteration was found only confined to the small intestine, since 
Zot does not affect the colon permeability. The selective effect of the toxin on the small 
intestine seems related to the regional distribution of the Zot receptors that are present in the 
jejunum and ileum, but not in the colon (Chaudhuri and Chatterjee, 2009c).  
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1.5.4.3   Accessory cholera enterotoxin (Ace) 
Ace is another toxin produced by V. cholerae, its open reading frame is located upstream of 
zot and ctx gene in the filamentous phage, CTXφ. The termination codon of ace overlaps 
with the initiation codon of zot, an arrangement involving translational coupling between ace 
and zot. The toxin comprises a 289 bp gene coding for 96 amino acids with a predicted 
molecular mass of about 11.3 kDa (Trucksis et al., 1993). The mechanism of action of Ace 
has been delineated in a human colonic tumor cell line, T84 cells (Trucksis et al., 2000). It 
has been suggested that Ace may contribute to an early phase of intestinal secretion in V. 
cholerae infection before the onset of the secretion stimulated by the more slowly acting 
cholera toxin (Trucksis et al., 2000). 
 
1.5.4.4   Shiga-like toxin (SLT) 
Shiga-like toxins (or verotoxins) in V. cholerae was reported by O’Brien et al., 1984 on the 
basis of cytotoxic activity of cell lysates towards HeLa cells, and this activity was found to 
be neutralized by antibody against purified Shiga toxin produced by Shigella dysenteriae 
type 1 (O'Brien and Holmes, 1987). SLT is moderate to high levels of heat-stable (56 °C, 15 
min) and cause cytotoxicity to certain cell lines, enterotoxic in rabbit ileal loops, and 
neurotoxic (causing limb paralysis and death) in rabbits and mice (Chaudhuri and Chatterjee, 
2009c). Genes encoding SLT have not been cloned from V. cholerae despite repeated efforts 
as there is no homology could be found in genome sequences of V. cholerae with SLT 
Shigella dysenteriae type 1 and slt-1 of E. coli (Chaudhuri and Chatterjee, 2009c). 
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1.6 Transmission and prevention of cholera 
1.6.1 Transmission of cholera  
Cholera can be transmitted through ingestion of contaminated food or water. In epidemics 
and endemics, the primary source of the contaminant may be the faeces of the infected 
humans, and food serve an important role as vehicle for the transmission (Estrada-Garcia and 
Mintz, 1996, Tauxe, 1998). Most of the vibrios will not survive the passage through stomach 
gastric acid, but the organisms hidden within the food particles are spared (Rabbani and 
Greenough, 1999). Besides, foods also serve as culture medium for V. cholerae to multiply 
and achieve sufficient dose for causing disease (Estrada-Garcia and Mintz, 1996). As 
mentioned earlier, V. cholerae could also survive within crustacean and many sea creatures, 
and the general preference to eat raw or partially cooked seafood makes seafood the most 
commonly implicated vehicle in foodborne cholera. 
 
1.6.2 Prevention of cholera 
The existence of environmental reservoirs of toxigenic V. cholerae means the organism is 
likely to persist indefinitely. As long as the organism persists, the potential for epidemic 
cholera exist, wherever and whenever conditions are ripe for sustained transmission. 
Therefore proactive steps should be taken to prevent the transmission of the disease. 
 
1.6.2.1  Disinfection and sanitation 
The success of control efforts depends on knowing the actual mechanisms or vehicles of 
transmission and having the tools available to block them. V. cholerae disseminate through 
contaminated food and water, hence the best way to prevent the disease is to provide clean 
water and food. The organisms can be killed through boiling of drinking water or 
chlorinating the water supply. Eating hot serving food also helps to prevent the spreading of 
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the disease. Generally, the practice of proper hygiene will help to prevent the spreading of 
the organism (Estrada-Garcia and Mintz, 1996). In the long term, improvements in water 
supply, sanitation, food safety and community awareness of preventive measures are the best 
means of preventing cholera and other diarrheal diseases. 
 
1.6.2.2  Immunization 
Immunization is the ideal prophylactic intervention for cholera prevention. There are two 
oral cholera vaccine currently available, WC/rBS - killed whole cells vaccine with a 
recombinant B subunit of CT and CVD103-HgR - live attenuated cholera vaccine (WHO, 
2001). However, these vaccines are for V. cholerae O1 serogroup and do not confer cross-
protection against toxigenic V. cholerae O139 serogroup (Tacket and Sack, 2008, WHO, 
2001). Hence, V. cholerae O139 serogroup may pose as a threat to the world as it is capable 
of causing cholera pandemic.  
 
1.7 Cholera vaccines 
The early attempt of cholera vaccine was by Ferran (1884) shortly after the discovery of V. 
cholerae by Koch. After Ferran, Haffkine also began to work on cholera vaccine and he was 
convinced of the efficacy of his vaccine as none of the immunized person developed cholera 
(Tacket and Sack, 2008). The vaccine, which was made of killed V. cholerae strains from 
both Inaba and Ogawa serotypes, was never recommended by WHO, but still may be 
available in some countries. Two types of cholera vaccines have been developed since then, 
a killed oral vaccine and a live attenuated oral vaccine; both have been shown to be safe, 
immunogenic and efficacious. 
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1.7.1 Immunity to V. cholerae 
It is believed that cholera is a non-inflamatory infection. There are often no gross changes to 
the intestinal mucosa or the architectural integrity of the small bowel. However, we discover 
that our V. cholerae strain of O139 serogroup causes pathological changes to the small 
intestine at high dose of 108 CFU in 1cm intestinal loop (Amin et al., 2009). There are also 
upregulation of pro-inflammatory cytokines production in the intestinal cells (Nandakumar 
et al., 2009, Stokes et al., 2004, Zhou et al., 2004) and migration of neutrophils to the lamina 
propria during acute cholera (Qadri et al., 2004).  
Study had demonstrated that V. cholerae infection induces protective immunity 
against subsequent infection (Kaper et al., 1995). It was suggested that secretory 
immunoglobulin A (sIgA) protects against colonization of the mucosa. Increase of antigen-
specific lymphocytes in circulation (Bhuiyan et al., 2009) and recruitment to intestinal 
mucosa leads to elevated sIgA secretion in intestinal mucosa. Serum vibriocidal antibody 
and anti-toxins antibodies were also elicited besides sIgA, which correclate with protective 
immune response. But these antibodies decrease to baseline levels one year after infection. 
Similarly, mucosal sIgA levels decrease to baseline levels in months after infection (Nelson 
et al., 2009). However, when challenged with V. cholerae antigens, anamnestic immune 
response was demonstrated with rapid increase in antibody secretion in the intestine. Hence, 
it is the anamnestic immune response that mediates protection against cholera, which also 
supported by presence of cholera induced memory B cell even after one year of cholera 
infection (Longini et al., 2002).  
 
1.7.2 Cytokines during infection 
Cytokines are central to the development of effective immunity against microbial pathogens. 
It is well documented that cytokines involvement in immune reaction during active infection. 
Different cytokines were secreted by the infected cells in response to the damage caused by 
the pathogen. The understanding of secreted cytokines by these cells during infection will 
